MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Developing Consumer-Managed Data Marketplace

SRAX (NASDAQ: SRAX), a digital marketing and consumer-data-management technology company, enables consumers to own their own data and be compensated for the release of that date. An article discussing the company reads, “SRAX’s focus is its consumer-powered, data-management platform that rewards consumers while enabling businesses to obtain fully informed, consumer opted-in data. Also issues of privacy and data ownership are of increasing concern to consumers. They expect to keep data private as privacy laws on both the state and federal level are putting the value and control of data back in the hands of consumers. Social platforms such as Facebook, Twitter, Snapchat, LinkedIn and others are facing backlash from consumers over privacy concerns. . . .SRAX’s BIGtoken solution enables consumers to own their own data and get remunerated for the release of their data. With BIGtoken’s secure platform, consumers have control over what data is shared, who can buy it and how it’s used (http://ibn.fm/PfdCb). Furthermore, businesses gain consumer data that is passed through numerous layers of verification for premier accuracy.”

To view the full article, visit http://ibn.fm/0grZF

About SRAX

SRAX is a digital marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring-revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing CancerQuest2020 Initiative

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently reported that its Helomics subsidiary is making headway toward its goal of developing an AI-driven predictive model of ovarian cancer (http://ibn.fm/mENY6). An article discussing the company reads, “This achievement will be a key milestone for the company’s CancerQuest2020 initiative. . . . CancerQuest2020 is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome leveraging Helomics’ huge knowledge base of tumor profiles. Predictive models embody the knowledge from these profiles to create a ‘computational expert’ or a ‘virtual patient’ that can be queried. Predictive models such as these are of high value to pharmaceutical companies as they can be used to quickly select patients for clinical trials and assess potential new drugs or biomarkers computationally (‘in silico’) before initiating expensive laboratory experiments. In short, Helomics’ predictive models will save time and money in the search for new targeted therapies. . . . Using the power of AI, the model draws on data generated from over 150,000 tumor cases.”

To view the full article, visit http://ibn.fm/t0WsP

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other) that contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled with a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform Kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Trxade Group, Inc.’s (NASDAQ: MEDS) Integral Role in Efforts to Combat COVID-19 Featured in NetworkNewsAudio Podcast

Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, was featured in an exclusive NetworkNewsWire (“NNW”) audio podcast, via NNW’s audio press release solutions suite. The podcast contains NNW editorial coverage titled, “Medical Supply Companies Take on Crucial Role in Combatting Coronavirus” (http://ibn.fm/moaKe). Among other companies providing different critical elements in combating COVID-19, the editorial features Trxade and its role in delivering products and facilitating services to combat the virus’ spread locally. According to the editorial, “Integral to the efforts of over ten thousand pharmacies to procure and deliver essential supplies, Trxade Group Inc. (NASDAQ: MEDS) plays an increasingly important role in that indispensable supply chain. An integrated pharmaceutical services company, Trxade provides the technology backbone for independent pharmacies across the nation, delivering buying power and cost savings.  Trxade offers a unique combination of products and services, including a web-based purchasing platform for transactions between independent pharmacists and drug distributors; a network of pharmacies with E-Hub software; a mail-order pharmacy; and warehouse and drug delivery services. This myriad of offerings puts the company in a strong position to support America’s patients and healthcare heroes with the products they desperately need.”

To listen to the podcast, visit http://ibn.fm/OEL2L

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (NASQAQ: MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to buyers and sellers of pharmaceuticals, makes healthcare services affordable and accessible across all 50 states, and steps in to meet today’s immediate demands. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms; the Trxade B2B trading platform with 12,100 registered pharmacies, a licensed virtual Wholesaler, affordable healthcare via its Bonum Health app or web-based telehealth services, and same day or mail order pharmacy delivery capabilities via its DelivMeds app featuring its extensive nationwide distribution network. For additional information, please visit www.Trxade.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Sigma Labs Inc. (NASDAQ: SGLB) Positioned to Meet Expected Post-COVID Demand for 3D Metal Printed Parts with In-Process QA Technology

• Sigma Labs provides critical in-process monitoring technology to unlock scalability needed to meet parts demand
• 3D printed medical devices of all source materials market forecast to reach $26 billion over two years
• As industry reacts to current crisis, demand for 3D metal printed parts expected to increase

From specialized surgical tools designed to meet a surgeon’s unique needs to customized cutting guides for knee replacements, the healthcare industry is poised to be transformed by additive manufacturing (AM), also known as 3D printing (http://ibn.fm/q3ROJ). However, scalability has been limited by the technology’s lack of in-process quality control monitoring. Sigma Labs Inc. (NASDAQ: SGLB), a company specializing in real-time quality assurance of 3D metal printing, presents a solution to alleviate the onerous burden of quality assurance in mass production – at a time when the 3D printed medical devices market is expected to reach $26 billion over the next two years.

While 3D printing technology (also known as additive manufacturing) has long been used to create product prototypes, the lack of product uniformity and onerous quality assurance costs had made engaging in mass production a pipe dream. Sigma Labs, one of the leading providers of third party in-process quality assurance software to the commercial 3D metal printing industry, has allowed companies to monitor the quality of each product part in the production process, layer by layer and in real time – leading to a dramatic decrease in error rates and higher manufacturing yields.

According to industry think-tank SME, the 3D printed medical devices sector – which already accounts for 17 percent of the total additive manufacturing (AM) market – will grow to roughly $26 billion over the next 24 months. A key segment spearheading growth in the sector has been the design and fabrication of replacement joints and artificial limbs. Over 30 million people worldwide are in need of artificial limbs and mobility devices, yet less than 20 percent have access to them, largely due to the extremely time-consuming and expensive process of producing customized prosthetics. 3D printing has sought to address this issue by enabling an ever-increasing number of patients, particularly from developing nations, to gain access to bespoke prosthetic limbs. Healthcare NGO e-NABLE has been one of the pioneers in the field, publishing free designs for prosthetic hands, which are available for anyone to print and can cost as little as $35 (http://ibn.fm/YddEE).

However, the industry’s prodigious growth rate has not been limited to well-documented manufacturing breakthroughs such as the design of hearing aids, dental implants and prostheses. In northern Italy’s Lombardy region, a shortage of ventilators in the midst of the viral outbreak was compounded by a lack of replacement valves for faulty machines. With medical suppliers unable to provide spare parts at short notice, 3D printing experts and local business owners were able to collaborate and come to the rescue by rapidly fabricating the replacement parts within a matter of hours (http://ibn.fm/E8xDs). Similarly, in the United States, Massachusetts-based Formlabs, a manufacturer of 3D printers, was able to swiftly reformat over 250 of their printers to produce 100 thousand nasal swabs for COVID-19 testing a day (http://ibn.fm/67WPy). With the scope of 3D printed medical devices widening on a daily basis, product safety has increasingly become a factor alongside other variables such as production cost, product longevity and functionality. As such, the need for a robust, efficient and easily implementable quality assurance process has become paramount.

To meet this requirement, Sigma Labs PrintRite3D(R) caters to the highly technical and precise nature of the Additive Manufacturing 3D metal branded equipment being created. In early April, the company launched the newest iteration of its revolutionary PrintRite3D(R) software, providing manufacturers with the ability to remotely monitor their 3D printing process in real-time while offering actionable information and AI-driven metrics on a production management user-interface platform. Moreover, Sigma’s technology can be used on 3D printers from multiple manufacturers to provide a consistent standard of quality assurance, thereby allowing for the technology to be deployed throughout a manufacturer’s supply chain (http://ibn.fm/ejfV5).

Following the launch and during a recent interview with Proactive Investors, Sigma Labs Chairman Mark Ruport went on to reaffirm that the company was now eyeing a “tremendous opportunity” to become the de facto standard for third party in-process quality assurance of metal parts production (http://ibn.fm/XnYS3).

The application of 3D printing within medical hardware and healthcare has allowed the industry to access critical components as and when they are needed – all at reduced cost, time, and wastage relative to traditional manufacturing methods. However, 3D printing will only truly surpass traditional techniques when the additive manufacturing industry moves from ‘post-process’ quality control to ‘in-process’ quality assurance. As one of the leaders in its field, Sigma Labs and its technological solutions are well positioned to capitalize on the industry’s explosive growth going forward.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Enters LOI to Acquire SkinScience Labs through Cannaworx

Pressure BioScience (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced a letter of intent (“LOI”) to acquire SkinScience Labs, Inc., parent company of the award-winning Dr. Denese skin care and anti-aging product lines. Per the update, the rights to acquire SkinScience Labs, which includes Dr. Denese SkinScience, is through Cannaworx, Inc., for which PBI announced plans to acquire on April 28, 2020. “The Dr. Denese SkinScience brand has reached top performing status on QVC for a skin care line, selling over 25 million units and receiving multiple QVC customer choice beauty awards,” PBI President and CEO Richard T. Schumacher said in the news release. “Adrienne’s tremendous brand recognition, regularly repeating customer base, and major existing sales momentum brings immediate accretive impact into the PBI portfolio – and we know that our UST nanoemulsions will create powerful new leverage and opportunities for her expanding product lines. Our team has worked very hard to bring this pivotal transition together for PBI and its shareholders, and we are very excited about the prospects for growth and value appreciation in our combined companies going forward.”

To view the full press release, visit http://ibn.fm/7E2GG

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life-sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Sigma Labs, Inc. (NASDAQ: SGLB) to Host Q1 Results Conference Call on May 14, 2020

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the additive manufacturing industry, today announced that it will host a conference call at 4:30 PM ET on Thursday, May 14, 2020, to discuss its results for the first quarter ended March 31, 2020. A press release detailing the results will be issued prior to the call that will be hosted by Sigma Labs Executive Chairman Mark Ruport, CEO John Rice and CFO Frank Orzechowski. Interested parties may access the call by dialing 1-877-407-9039 (Toll-free) or 1-201-689-8470 (International) and entering Conference ID: 13702566. The conference call will be broadcast live and available for replay at http://ibn.fm/IXqBf and via the investor relations section of the company’s website.

To view the full press release, visit http://ibn.fm/viEcf

About Sigma Labs

Sigma Labs, Inc. is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D(R) for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs’ software product is a major catalyst for the acceleration and adoption of 3D metal printing. For more information, visit the company’s website at www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Featured in Dougherty & Company LLC Research Report

Trxade Group (NASDAQ: MEDS) was featured in a recent equity research report published by Dougherty & Company LLC. The report reads, “We are initiating coverage of Trxade with a Buy rating and Price Target of $12. MEDS’ primary offering is a web-based platform connecting large suppliers of branded and generic drugs with retail and independent pharmacies. The platform offers full price transparency, comparing the prices and availability across a variety of suppliers. Its latest offering is a direct-to-consumer application equipped with telemedicine visits which includes home delivery of medications. MEDS nearly doubled revenue in 2019 and we model the company increasing sales at close to a 40% clip in 2020, while profitable for several quarters. We view the stock as a compelling, under-the-radar idea for small-cap growth investors seeking exposure to digital health and telemedicine. Our $12 Price Target is based on a 6x multiple on our 2021 forecast, a slightly lower multiple than comps which we justify with a small cap discount, but considering also MEDS’ superior growth rate.”

To request access to the full report, visit http://ibn.fm/LQ1QX

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (NASQAQ: MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to buyers and sellers of pharmaceuticals, makes healthcare services affordable and accessible across all 50 states, and steps in to meet today’s immediate demands. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms; the Trxade B2B trading platform with 12,100 registered pharmacies, a licensed virtual Wholesaler, affordable healthcare via its Bonum Health app or web-based telehealth services, and same day or mail order pharmacy delivery capabilities via its DelivMeds app featuring its extensive nationwide distribution network. For additional information, please visit www.Trxade.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – iClick Interactive Asia Group Limited (NASDAQ: ICLK) Named in CIO Advisor APAC’s Top 10 Ad Management Companies 2020

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced that it has been selected as one of the “Top 10 Ad Management Companies 2020” by CIO Advisor APAC. Last year, the company was listed by the publication as Top 10 APAC Digital Marketing Solution Providers-2019. In addition, Sammy Hsieh, iClick Co-founder and Chairman of the Board of Directors, was featured in the April 2020 edition of CIO Advisor’s Ad Management magazine highlighting the company’s services and achievements in the advertising industry. “We are delighted to receive these prestigious accolades which recognize our strong capabilities in both digital marketing and ad management. One of iClick’s fundamental goals is to use advanced marketing technologies to help international brands reach the right audiences in China and optimize their business and marketing efforts. Through our Integrated Enterprise and Marketing Cloud Platform combined with our close understanding of market trends, we help customers turn online and offline data into actionable and monetizable insights,” iClick Co-founder and Chairman of the Board of Directors Sammy Hsieh stated in the news release.

To view the full press release, visit http://ibn.fm/o6ET1

About iClick Interactive Asia Group

iClick Interactive Asia Group Limited is an independent, online marketing and enterprise-data-solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, the company’s proprietary platform possesses omni-channel marketing capabilities and fulfills various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and currently operates in 10 locations worldwide, including Asia and Europe. For more information, visit the company’s website at www.i-Click.com.

NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Inks Binding LOI to Acquire Cannaworx, Inc.

Pressure BioScience (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform-technology solutions to the worldwide life sciences and other industries, today announced that it has signed a binding letter of intent (“LOI”) to merge with Cannaworx, Inc. (USA) and its diverse portfolio of products and intellectual property. The merger will combine Cannaworx’s proprietary portfolio of consumer products with the application of PBIO’s breakthrough ultra shear technology (“UST”). Following the merge, the company will utilize its extensive intellectual property portfolio, consisting of a proprietary pressure platform, nanotechnology and advanced delivery systems, to disrupt markets including the booming U.S. hemp-derived CBD market. “We have been actively searching for an opportunity to participate in the end-product growth and upside we believe our UST platform creates and delivers. We are very excited to bring our companies together for what we believe to be a momentous inflection point in significant new growth and increased shareholder value,” PBIO president and CEO Richard T. Schumacher stated in the news release.

To view the full press release, visit http://ibn.fm/XX3GT

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life-sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Why Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Is ‘One to Watch’

Lakewood, Colorado-based Energy Fuels (NYSE American: UUUU) (TSX: EFR) is the largest producer of uranium in the United States and the leading conventional producer of vanadium; both elements have been designated by the U.S. government as critical minerals. A recent article discussing the company reads, “As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.”

To view the full article, visit http://ibn.fm/e5s3A

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the United States today, has a licensed capacity of over 8 million pounds of U3O8 per year and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is in operation and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is currently on standby. In addition to these production facilities, Energy Fuels also has one of the largest NI 43-101 compliant, uranium resource portfolios in the country; the company also has several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Trxade Group, Inc. (NASDAQ: MEDS) Announces Engagement of MZ Group to Expand Strategic Communications Program Across Key Markets

Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, today announced its engagement of international investor relations specialists MZ Group (“MZ”) to expand its comprehensive strategic investor relations and financial communications program across all key markets. According to the update, MZ Group will work closely with Trxade Group management in the development and implementation of a comprehensive capital markets strategy designed to increase the Company’s visibility throughout the investment community. “This is an exciting time for Trxade Group, having achieved key growth milestones in 2019, positioning us for a breakout year in 2020 as we continue to scale our proprietary platform,” Trxade Group chairman and CEO Suren Ajjarapu said in the news release. “The importance of our trading platform has been validated by the market, having grown our footprint of registered independent pharmacy members to 40% in 2019 to over 12,100 locations nationwide. These pharmacies have seen purchasing efficiencies on our platform before and during the COVID-19 pandemic, as we uniquely positioned to supply COVID-19 test kits in time to make a difference in the lives of their patients. Together with MZ Group, we will enhance our investor communications and awareness efforts, while simultaneously working to create sustainable value for our shareholders over the long-term.”

To view the full press release, visit http://ibn.fm/p2JQW

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (NASQAQ: MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to buyers and sellers of pharmaceuticals, makes healthcare services affordable and accessible across all 50 states, and steps in to meet today’s immediate demands. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms; the Trxade B2B trading platform with 12,100 registered pharmacies, a licensed virtual Wholesaler, affordable healthcare via its Bonum Health app or web-based telehealth services, and same day or mail order pharmacy delivery capabilities via its DelivMeds app featuring its extensive nationwide distribution network. For additional information, please visit www.Trxade.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Youngevity International, Inc. (NASDAQ: YGYI) Subsidiary’s Hemp-Derived Coffee Product Line Now Available on Amazon.com

Youngevity International (NASDAQ: YGYI), a multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise, commercial hemp enterprise and multi-channel lifestyle company, today announced that its hemp derived coffee brand Javalution is now available for immediate shipping at Amazon.com. The full line of hemp coffee is available for purchase on Amazon in the flavors House Blend, Donut Shop Blend, French Vanilla, and Dark Roast. “We already see the Javalution Hemp Derived K-Cups showing up at the top of the Amazon search engines which has us optimistic about Javalution’s sales potential within this platform,” YGYI president and CFO Dave Briskie stated in the news release. “We are excited for the Amazon customer to experience the flavor profile of Javalution Hemp Derived Coffees.”

To view the full press release, visit http://ibn.fm/8hUAq

About Youngevity International, Inc.

Youngevity International, Inc. is a multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise. The company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity. YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For more information, please visit www.YGYI.com.

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Sigma Labs Inc. (NASDAQ: SGLB) Breakthrough Technology Positioned to Enhance Sustainability for Manufacturing Industry

• SGLB’s PrintRite3D(R) technology supports, enables wider adoption of 3D printing for scaled manufacturing
• Fourth industrial revolution’s new manufacturing technologies can usher in a cleaner, more sustainable world
• One of simple but substantial solutions that add to sustainability of 3D printing is assembly consolidation, or combining of several parts into fewer, multifunctional assemblies

In an industry that is “forever changing the way products are made” – specifically as it pertains to ushering in a cleaner, more sustainable world – Sigma Labs Inc. (NASDAQ: SGLB) stands out as a leading developer of quality-assurance software in the commercial 3D-metal-printing space. A recent World Economic Forum article, titled ‘These 4 Simple Solutions Can Help Make the Manufacturing Industry More Sustainable’, recognizes 3D printing as one such solution to enhance the industry’s success – and companies like SGLB are well positioned to help (http://ibn.fm/yOKq7).

The fourth industrial revolution involves more than the transformative impact new manufacturing technologies – such as 3D printing – will have on companies and consumers, the article observes. “It’s also about how industry can usher in a cleaner, more sustainable world.”

“It’s foolish to deny the planet is rapidly approaching the day when the consequences of climate change will be unavoidable,” the article continues. “The question now facing many business leaders is whether – and how – we can both continue to build value for our shareholders and mitigate our impact on the natural world.”

One of the simple solutions that add to the sustainability of 3D printing is assembly consolidation, or the combining of several parts into fewer, multifunctional assemblies. “With fewer parts to transport, the process can make shipping networks more efficient, significantly reducing CO2 emissions,” the article states, going on to point out that, though the geometric flexibility of 3D printing makes it possible to create these multifunctional parts, additive manufacturing (AM) is still in its infancy when it comes to manufacturing production parts.

“In part, that’s because the story of the additive industry is really one of three distinct growth curves,” the article continues. “The first, beginning in the early 1990s, largely focused on research and development of the new additive technology. Today, the industry stands at the start of a new S-curve, which will see wider adoption of 3D printing for manufacturing, forever changing the way products are made.”

Sigma Labs has been on the cutting edge of the research and development taking place in the AM space and is already actively involved in supporting and encouraging the wider adoption of 3D metal printing through its PrintRite3D(R) product line. SGLB’s proprietary technology resolves the major roadblocks and costly quality-control challenges that slow down and even prevent the 3D manufacture of precision metal parts. The company’s breakthrough, computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance during production and allowing errors to be corrected in real-time.

Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided-inspection (CAI) solutions known as PrintRite3D for 3D-advanced manufacturing technologies. SGLB’s advanced, computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time.

For more information about Sigma Labs, please visit www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html